Search results for " Venere"

showing 10 items of 540 documents

A case of cefditoren‐induced Acute Generalized Exanthematous Pustulosis during COVID‐19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an …

2020

Abstract We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID‐19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.

0301 basic medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyDermatologymedicine.disease_causeLetter to EditorSARS‐CoV‐2030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCOVID‐19PandemicSeverity of illnessmedicineSevere Cutaneous Adverse Reactions (SCARs)Coronavirusbusiness.industryFollow up studiesAcute Generalized Exanthematous Pustulosis (AGEP)Acute generalized exanthematous pustulosismedicine.diseaseDermatologyInfectious DiseasesbusinessCefditorenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

2020

Atopic dermatitis (AD) is characterized by chronic, relapsing, pruritic skin inflammation and does not have a well-understood pathogenesis. In this study, we addressed the contribution of adipokines to AD eczema based on the assessment of blood levels of adiponectin, resistin, leptin, lipocalin-2, and vaspin in adult non-obese patients suffering from chronic extrinsic childhood-onset AD. We investigated 49 AD patients with a median age of 37 years. The control group consisted of 30 age-matched healthy subjects. Adipokines were assessed in the serum by ELISA assays and the severity of AD with the SCORing Atopic Dermatitis (SCORAD) index. We found that adiponectin and resistin decreased and l…

0301 basic medicineAdiponectinmedicine.diagnostic_testbusiness.industryLeptinnutritional and metabolic diseasesAdipokineGeneral MedicineDiseaseAtopic dermatitismedicine.diseasePathogenesis030207 dermatology & venereal diseases03 medical and health sciences030104 developmental biology0302 clinical medicineImmunologyMedicineResistinSCORADbusinesshormones hormone substitutes and hormone antagonistsJournal of Clinical Medicine
researchProduct

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct

Identification of Candida auris and related species by multiplex PCR based on unique GPI protein‐encoding genes

2020

Background The pathogen Candida auris is rapidly gaining clinical importance because of its resistance to antifungal treatments and its persistence in hospital environments. Early and accurate diagnosis of C. auris infections is crucial, however, the fungus has often been misidentified by commercial systems. Objectives To develop conventional and real-time PCR methods for accurate and rapid identification of C. auris and its discrimination from closely related species by exploiting the uniqueness of certain glycosylphosphatidylinositol-modified protein-encoding genes. Methods Species-specific primers for two unique putative GPI protein-encoding genes per species were designed for C. auris, …

0301 basic medicineAntifungal AgentsGlycosylphosphatidylinositolsGenes Fungal030106 microbiologyDermatologyBiologyReal-Time Polymerase Chain ReactionFungal Proteins030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSpecies SpecificityMultiplex polymerase chain reactionHumansMultiplexMycological Typing TechniquesGenePathogenCandidaDNA PrimersGeneticsCandidiasisReproducibility of ResultsGeneral MedicineAmpliconCorpus albicansInfectious DiseasesCandida aurisIndansIdentification (biology)Multiplex Polymerase Chain ReactionMycoses
researchProduct

IL-17A/F in Leishmania major-resistant C57BL/6 mice.

2019

Proinflammatory IL-17 plays an important role in various diseases and defence against extracellular microorganisms. Healing of leishmaniasis is promoted by Th1/Tc1 cells, whereas Th2/Treg are associated with worsened disease outcome. In addition, high expression of IL-17A in Leishmania-susceptible BALB/c and artificial overexpression of IL-17A in T cells in resistant C57BL/6 mice worsened disease outcome. Since C57BL/6 mice lacking only IL-17A exhibited no phenotype, and IL-17A and IL-17F share similar receptors, but differentially regulate chemokine secretion, we studied mice lacking both IL-17A and IL-17F (IL-17A/F-/- ) in infections with Leishmania major. Interestingly, lesion volumes an…

0301 basic medicineC57BL/6CD4-Positive T-LymphocytesMaleDermatologyBiochemistryProinflammatory cytokineLesion030207 dermatology & venereal diseases03 medical and health sciencesMice0302 clinical medicineTh2 CellsmedicineAnimalsSecretionLeishmania majorReceptorMolecular BiologyIntraepithelial LymphocytesLeishmaniasisCrosses GeneticLeishmaniaMice Inbred BALB CbiologyInterleukin-17Th1 Cellsbiology.organism_classificationPhenotypeMice Inbred C57BL030104 developmental biologyPhenotypeChemokine secretionImmunologyDisease ProgressionCytokinesFemalemedicine.symptomExperimental dermatology
researchProduct

Antibacterial properties and reduction of MRSA biofilm with a dressing combining polyabsorbent fibres and a silver matrix

2016

Objective: This study was designed to evaluate the antibacterial activity of a wound dressing which combines polyacrylate fibres and a silver lipido-colloid matrix (UrgoClean Ag, silver polyabsorbent dressing), against biofilm of methicillin-resistant Staphylococcus aureus (MRSA). Method: Samples of silver polyabsorbent dressing and the neutral form of this dressing (UrgoClean) were applied to biofilms of MRSA formed on a collagen I-coated surface, cultured for 24 hours. Different exposure times were tested (1, 2, 4 and 7 days) without dressing change. The biofilm reduction was quantified by using culture methods and by confocal laser scanning microscopy experiments. Results: The applicatio…

0301 basic medicineColonizationNursing (miscellaneous)ResistanceMechanical effectMRSAmedicine.disease_causeDressing changeMatrix (chemical analysis)030207 dermatology & venereal diseases0302 clinical medicine[SDV.IDA]Life Sciences [q-bio]/Food engineeringContaining wound dressingseducation.field_of_studyBiofilm[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringSilver CompoundsHydrogelsAnti-Bacterial AgentsStaphylococcus aureusSilver-containing wound dressingPseudomonas aeruginosaPolyacrylate fibresAntibacterial activityMethicillin-Resistant Staphylococcus aureus030106 microbiologyPopulationStaphylococcus-aureus biofilmBurnMicrobiology03 medical and health sciencesmedicineConfocal laser scanning microscopyHumansPseudomonas-aeruginosa biofilmeducationWound HealingBacteriaPseudomonas aeruginosabusiness.industryIn-vitro modelHuman keratinocytesBiofilmbiochemical phenomena metabolism and nutritionBandagesBiofilmsWound InfectionAntimicrobial efficacyFundamentals and skillsAntibacterial activitybusinessNuclear chemistry
researchProduct

Aryl Hydrocarbon Receptor in Keratinocytes Is Essential for Murine Skin Barrier Integrity.

2016

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in adaptive cell functions, and it is highly active in the epidermis. AhR ligands can accelerate keratinocyte differentiation, but the precise role of AhR in the skin barrier is unknown. Our study showed that transepidermal water loss, a parameter of skin barrier integrity, is high in AhR-deficient mice. Experiments with conditionally AhR-deficient mouse lines identified keratinocytes as the primary cell population responsible for high transepidermal water loss. Electron microscopy showed weaker intercellular connectivity in the epidermis of keratinocytes in AhR-knockout mice, and gene expression analysi…

0301 basic medicineKeratinocytesCellular differentiationPopulationDermatologyBiochemistrySkin Diseases030207 dermatology & venereal diseases03 medical and health sciencesMice0302 clinical medicinemedicineBasic Helix-Loop-Helix Transcription FactorsAnimalseducationReceptorMolecular BiologyTranscription factorCells CulturedTransepidermal water losseducation.field_of_studybiologyEpidermis (botany)ChemistryCell DifferentiationCell BiologyDNArespiratory systemAryl hydrocarbon receptorrespiratory tract diseasesCell biologyMice Inbred C57BLDisease Models AnimalMicroscopy Electron030104 developmental biologymedicine.anatomical_structureBiochemistryGene Expression RegulationReceptors Aryl Hydrocarbonbiology.proteinKeratinocyteThe Journal of investigative dermatology
researchProduct

Zinc(II) Complexes of Amino Acids as New Active Ingredients for Anti-Acne Dermatological Preparations.

2021

Zinc compounds have a number of beneficial properties for the skin, including antimicrobial, sebostatic and demulcent activities. The aim of the study was to develop new anti-acne preparations containing zinc–amino acid complexes as active ingredients. Firstly, the cytotoxicity of the zinc complexes was evaluated against human skin fibroblasts (1BR.3.N cell line) and human epidermal keratinocyte cell lines, and their antimicrobial activity was determined against Cutibacterium acnes. Then, zinc complexes of glycine and histidine were selected to create original gel formulations. The stability (by measuring pH, density and viscosity), microbiological purity (referring to PN-EN ISO standards) …

0301 basic medicineKeratinocytesGlycineSkin Creamchemistry.chemical_elementHuman skinZincCatalysisArticleCell LineInorganic Chemistrylcsh:Chemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineantibacterial activityAcne VulgarismedicineHumansHistidinePhysical and Theoretical Chemistryzinc(II) complexesMolecular Biologylcsh:QH301-705.5acneSpectroscopyAcneHistidineSkinActive ingredientamino acidsChromatographyOrganic Chemistryskin toleranceGeneral MedicinePropionibacteriaceaeAntimicrobialmedicine.diseaseComputer Science ApplicationsAnti-Bacterial AgentsZinc030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Zinc CompoundsGlycinecytotoxicityAntibacterial activityInternational journal of molecular sciences
researchProduct

Expanding the clinical spectrum of mosaic BRAF skin phenotypes

2021

BRAF postzygotic activating mutations have been found in 50% of cases of syringocystadenoma papilliferum (SCAP)1 and in phacomatosis pigmentokeratotica (PPK)2,3 , also possibly caused by HRAS4 mutations. BRAF is a RAS-activating serine/threonine kinase of the MAP kinase pathway, resulting in cell growth and proliferation. BRAF mutations, particularly p.(Val600Glu), are frequently identified in melanoma and other human cancers5 . We report clinical presentations of three patients with postzygotic BRAF mutations in affected skin, identified by next generation sequencing (NGS).

0301 basic medicineMAPK/ERK pathwayProto-Oncogene Proteins B-rafendocrine system diseases[SDV]Life Sciences [q-bio]DermatologyDNA sequencingSerine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineThreonineneoplasmsComputingMilieux_MISCELLANEOUSSkinKinasebusiness.industryMelanomamedicine.diseasePhenotypedigestive system diseases3. Good health030104 developmental biologyInfectious DiseasesPhenotypeMutationCancer researchbusinessSyringocystadenoma papilliferum
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct